Here is our list of the 11 Best Gene Therapy Stocks to Buy According to Analysts.

LUXTURNA has significant market potential due to the high unmet need for effective treatments in rare genetic conditions. With its FDA approval for specific mutations in the RPE65 gene, it offers ...

DelveInsight's "LUXTURNA Market Size, Forecast, and Market Insight Report" highlights the details around LUXTURNA, a one-time ...

Recently, the research team led by Professor Zhang Zhongtao and Professor Yao Hongwei from the General Surgery Center at ...

The authors have generated important resources such as a reference dataset of early primate development by utilizing single-cell transcriptomic technology together with induced pluripotent stem cells ...

China’s National Medical Products Administration (NMPA) has granted conditional approval for Hutchmed’s Tazverik ...

Oxford, UK - 21 March 2025: OXB (LSE: OXB) (the "Company"), a quality and innovation-led cell and gene therapy CDMO, today ...

I T WAS AFTER tripping on hallucinogenic mushrooms that Christian Angermayer realised he had a personal mission to help the ...

By replacing the defective gene associated with Dravet syndrome in mice, scientists successfully alleviated symptoms without ...

In a groundbreaking advancement for families grappling with the challenges of Dravet syndrome, a rare and life-altering form ...

Scientists developed a promising gene replacement therapy for Dravet syndrome in mice. The therapy alleviated symptoms ...

Snakes are one of the most dangerous yet fascinating reptiles. With their stunning patterns, slithering noises and poisonous ...